Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

The objective of this study was to evaluate whether interleukin-2 (IL-2) receptor expression on CD56(bright) natural killer (NK) cells predicted CD56(bright) NK cell expansion and therapeutic response to daclizumab (DAC) in multiple sclerosis (MS). DAC exposure, CD56(bright) NK cell counts, IL-2 rec...

Full description

Bibliographic Details

Published in:	Multiple sclerosis Vol. 17; no. 12; p. 1441
Main Authors:	Sheridan, James P, Zhang, Ying, Riester, Katherine, Tang, Meina T, Efros, Lyubov, Shi, Jia, Harris, Jeffrey, Vexler, Vladimir, Elkins, Jacob S
Format:	Journal Article
Language:	English
Published:	England 01.12.2011
Subjects:	Antibodies, Monoclonal, Humanized - therapeutic use CD56 Antigen - analysis Cell Proliferation - drug effects Humans Immunoglobulin G - therapeutic use Interleukin-2 Receptor alpha Subunit - metabolism Interleukin-2 Receptor beta Subunit - metabolism Killer Cells, Natural - immunology Killer Cells, Natural - metabolism Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Multiple Sclerosis - metabolism
ISSN:	1477-0970, 1477-0970
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!